OPB 111001

Drug Profile

OPB 111001

Alternative Names: OPB-111001

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Discontinued Prostate cancer

Most Recent Events

  • 15 Feb 2016 Phase-I development for Solid tumours is ongoing in European Union (PO)
  • 28 Apr 2015 Otsuka suspends a phase I/II trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in United Kingdom (NCT02042885)
  • 22 Jan 2014 Phase-I/II clinical trials in Solid tumours (late-stage disease, second-line therapy or greater) in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top